# NCT02716116 (NCT02716116)

> A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02716116
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: TAK-788
- Enrollment: 324
- Primary outcome: Part 1, Dose Escalation Component: Recommended Phase 2 Dose (RP2D) of Orally Administered TAK-788
- Primary outcome: Part 2, Expansion Cohorts 1, 2, 4, 5 and 7: Confirmed Objective Response Rate (ORR) Assessed by the Investigator
- Primary outcome: Part 2, Expansion Cohort 3: Intracranial ORR (iORR) Assessed by Independent Review Committee (IRC)
- Primary outcome: Part 2, Expansion Cohort 6: Confirmed ORR Assessed by IRC
- Primary outcome: Part 3, Extension Cohort: Confirmed ORR Assessed by IRC

## Indexed commentary on NCT02716116 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02716116